Most Recent Articles about Amgen
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent http://www.zacks.com/stock/news/360917/regeneron-sanofi-get-ec-nod-for-label-expansion-of-praluent?cid=CS-ZC-FT-360917 Mar 18, 2019 - Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Roche Gets Approval for Label Expansion of MabThera in Europe http://www.zacks.com/stock/news/359892/roche-gets-approval-for-label-expansion-of-mabthera-in-europe?cid=CS-ZC-FT-359892 Mar 15, 2019 - Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.
AMGN: BMO Capital Markets starts at Outperform http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20190315120125 Mar 15, 2019 - BMO Capital Markets issues rating change for AMGN

Related Companies

Name Exchange Price Mkt Cap
GILD Gilead Sciences, Inc. NASDAQ $72.78 $94.35B
BIIB Biogen Inc. NASDAQ $334.44 $67.37B
SGEN Seattle Genetics, Inc. NASDAQ $76.15 $12.09B
NBIX Neurocrine Biosciences, Inc. NASDAQ $117.38 $10.62B
QGEN Qiagen N.V. NASDAQ $37.42 $8.5B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)